Pathophysiology, Genetics & Classification

Question	Answer
1. What is the fundamental primary pathological lesion in Kawasaki Disease?	A systemic medium-vessel necrotizing arteritis with a marked predilection for the coronary arteries, leading to destruction of the arterial media and internal elastic lamina.
2. Which immune cell infiltrates the coronary arterial walls during the acute hyperacute phase (Days 0–9)?	Neutrophils predominantly infiltrate the adventitia and perivascular tissue, followed rapidly by an influx of CD8+ T lymphocytes, macrophages, and IgA-producing plasma cells.
3. What is the key molecular driver responsible for the intense vascular inflammation and elastin destruction?	Matrix metalloproteinases (MMPs), specifically MMP-9 and MMP-2, secreted by infiltrating macrophages and neutrophils, degrade extracellular matrix and elastic fibers.
4. How does the adaptive immune system contribute to arterial aneurysm formation?	Oligoclonal expansion of IgA plasma cells and T-cells in coronary artery lesions indicates a driven antigen-specific adaptive immune response, targeting intracellular stress proteins.
5. What is the cross-reactive molecular mimicry mechanism underlying BCG scar reactivation in Indian infants?	Cross-reactivity between human endothelial Heat Shock Protein 63 (HSP63) upregulated during systemic stress and mycobacterial Heat Shock Protein 65 (HSP65) retained in the BCG scar.
6. What is the hallmark histopathological change found in coronary arteries during the subacute/convalescent stage (Weeks 2–4)?	Granulation tissue formation, myofibroblast proliferation, and intimal thickening that can cause progressive luminal stenosis even as acute inflammation subsides.
7. Which cytokine profile dominates the systemic inflammatory cascade of acute Kawasaki Disease?	A profound Th1 and Th17 cytokine storm characterized by massive elevations of TNF-alpha, IL-1 beta, IL-6, and Interferon-gamma.
8. What genetic susceptibility locus shows the strongest and most consistent association with Kawasaki Disease globally?	Single nucleotide polymorphisms (SNPs) in the Inositol 1,4,5-trisphosphate 3-kinase C (ITPKC) gene, which downregulates T-cell activation.
9. How does CASP3 genetic polymorphism influence Kawasaki Disease susceptibility and coronary outcomes?	Variants in the Caspase-3 (CASP3) gene alter apoptosis regulation in vascular smooth muscle cells, increasing susceptibility to coronary arterial wall remodeling.
10. What anatomical layer of the coronary artery is the first to be structurally disrupted during acute vasculitis?	The tunica adventitia, which exhibits intense perivascular inflammation before the inflammatory process extends inward through the media to the intima.
11. What distinguishes Kawasaki Disease vasculitis histologically from typical ANCA-associated small vessel vasculitis?	Kawasaki Disease is a true neutrophil- and macrophage-driven panarteritis of medium-sized muscular arteries lacking antineutrophil cytoplasmic antibodies and necrotizing granulomas.
12. How does the vascular endothelial growth factor (VEGF) pathway contribute to coronary lesion pathophysiology?	Markedly elevated serum VEGF levels drive neoangiogenesis within the damaged arterial wall and promote increased vascular permeability, contributing to aneurysm formation.
13. What structural modification occurs in the late chronic stage (Months to Years) of a resolved Kawasaki aneurysm?	Fibrotic scarring, calcific degeneration, and luminal occlusion or recanalization via organized thrombi.
14. VIVA TRAP: Is Kawasaki Disease classified primarily as an autoimmune disease or an autoinflammatory vasculitis?	NEVER classify it as a classic autoimmune disease; it is categorized as an acute, self-limited systemic vasculitis triggered by an abnormal innate and adaptive immune response to an environmental agent in genetically susceptible hosts.
15. What is the histopathological hallmark of the chronic healing phase (Stage IV, beyond Day 40)?	Fibrosis and scarring of all three arterial layers with luminal stenosis or obstruction, with complete absence of active acute inflammatory cells.
16. Why are infants under 6 months disproportionately at risk of developing delayed or atypical Kawasaki disease?	Immature mucosal immune responses and waning maternal transplacental antibodies modify the classical clinical presentation while retaining high vascular vulnerability.
17. What role do Toll-like Receptors (TLRs) play in the innate immune activation of Kawasaki Disease?	Upregulation of TLR2 and TLR4 on macrophages and dendritic cells by microbial ligands initiates the downstream NF-kB inflammatory cascade.
18. What is the exact sequence of histological stages of Kawasaki vasculitis defined by Landing and Larson?	Stage 1: Perivasculitis and adventititis; Stage 2: Pansitis with necrosis; Stage 3: Granulation tissue formation and subacute remodeling; Stage 4: Scarring and chronic luminal healing.
19. How do genetic variations in the FCGR2A gene modify IVIG therapeutic responsiveness in Kawasaki Disease patients?	Polymorphisms in Fc-gamma receptor IIa affect the clearance and anti-inflammatory efficacy of therapeutic pooled intravenous immunoglobulins, predisposing to IVIG resistance.

Clinical History & Bedside Evaluation

Question	Answer
1. What is the classic age range of peak incidence for Kawasaki Disease, and why does it rarely present in neonates?	1. Peak incidence is between 6 months and 5 years of age, with roughly 80-85% of cases occurring in children under 5 years. 2. Neonates are rarely affected due to passive protection from transplacentally acquired maternal IgG antibodies.
2. What is the typical chronological fever duration threshold required by AHA criteria before diagnosing classic Kawasaki Disease?	Fever must persist for at least 5 consecutive days, though expert clinicians can establish the diagnosis on Day 4 if four or more principal clinical criteria are fully manifest.
3. How does the quality and response of the fever in Kawasaki Disease clinically differentiate it from typical viral pharyngitis?	1. The fever is characteristically high-grade, persistent, and remittent (102-104°F). 2. It is notoriously unyielding to standard doses of antipyretics and broad-spectrum antibiotic therapy.
4. What specific anatomical distribution and morphological features characterize the conjunctival injection of Kawasaki Disease?	1. It is a bilateral, non-exudative bulbar conjunctival injection. 2. It characteristically spares the limbic margin (perilimbal sparing) and is unaccompanied by purulent discharge or corneal ulceration.
5. What are the distinct clinical features of oral mucosal involvement that separate Kawasaki Disease from viral enanthems?	1. Fiery red erythema of the oral and pharyngeal mucosa. 2. Dry, fissured, cracked, and bleeding lips accompanied by hypertrophied lingual papillae on a red base known as a "strawberry tongue."
6. How do the extremity changes evolve chronologically between the acute and convalescent phases of Kawasaki Disease?	1. The acute phase presents with tense, brawny induration and painful erythema of palms and soles causing refusal to bear weight. 2. The convalescent phase features characteristic periungual desquamation (peeling) of fingers and toes starting 2 to 3 weeks after onset.
7. What are the key dermatological features and perineal characteristics of the polymorphous exanthem in Kawasaki Disease?	1. It is a non-vesicular, maculopapular, scarlatiniform, or erythema multiforme-like rash distributed over the trunk and extremities. 2. It shows prominent accentuation and early desquamation in the perineal diaper region.
8. What specific physical characteristics distinguish the cervical lymphadenopathy of Kawasaki Disease from acute bacterial cervical adenitis?	1. It typically presents as a solitary, firm, non-suppurative anterior cervical lymph node. 2. It must measure at least 1.5 cm in diameter and is usually unilateral.
9. What is the clinical significance of BCG scar reactivation in an infant presenting with prolonged fever in India?	1. It is a highly sensitive (>75%) and specific (>90%) early sign of Kawasaki Disease in BCG-vaccinated infants aged 3 to 24 months. 2. It manifests as sudden erythema, induration, and crusting over a previously quiescent BCG vaccination scar due to cross-reactive immune mechanisms.
10. What dietary recall and feeding history inquiries are vital during the bedside evaluation of a suspected Kawasaki patient?	1. Assessment of fluid intake and signs of dehydration due to high fever and painful oral mucosal lesions. 2. Documentation of any recent introduction of new foods or potential toxic exposures to rule out differential diagnoses like Stevens-Johnson syndrome or toxic shock syndrome.
11. How do perinatal and developmental histories contribute to the evaluation and risk stratification of a young infant with Kawasaki Disease?	1. Perinatal history helps rule out congenital infections and verifies neonatal BCG vaccination status for scar evaluation. 2. Developmental milestones establish baseline neurological status, ensuring systemic inflammation or irritability is properly contextualized.
12. What specific features should be actively sought in the family pedigree during a Kawasaki Disease history evaluation?	1. A family history of autoimmune disorders, coronary artery disease at a young age, or sibling history of Kawasaki Disease. 2. Positive family history highlights genetic susceptibility and familial clustering, which is well-documented in certain populations.
13. What are the major red flags in history that immediately steer the clinician away from Kawasaki Disease toward a differential diagnosis?	1. Presence of exudative pharyngitis, generalized vesicular or bullous skin lesions, or prominent generalized lymphadenopathy. 2. These features strongly point toward alternative diagnoses such as adenovirus, measles, Stevens-Johnson syndrome, or systemic onset Juvenile Idiopathic Arthritis.
14. VIVA TRAP: 15. VIVA TRAP: Can a patient be diagnosed with complete Kawasaki Disease on the third day of continuous high-grade fever if all five principal criteria are fully present?	NO. By strict AHA definition, fever must be present for a minimum of 5 days, although experienced clinicians may initiate therapy and diagnose earlier on Day 4 if classic criteria are met to prevent coronary complications.
15. How does the clinical presentation of incomplete Kawasaki Disease differ fundamentally from classic cases during bedside evaluation?	1. Patients present with persistent fever for ≥ 5 days accompanied by only 2 or 3 of the principal clinical criteria. 2. They require mandatory laboratory and echocardiographic evaluation to uncover occult systemic inflammation and prevent delayed diagnosis.
16. What predisposing epidemiological risk factors, including ethnicity and geography, must be gathered during history taking?	1. Asian ethnicity (particularly Japanese, Korean, and Indian subcontinental ancestry) carries the highest population incidence. 2. Age between 6 months and 5 years and male sex (male-to-female ratio of roughly 1.5:1) are established demographic risk factors.
17. What gastrointestinal symptoms in history are frequently associated with acute Kawasaki Disease and can mimic an acute abdomen?	1. Irritability, abdominal pain, vomiting, and diarrhea. 2. Hydrops of the gallbladder, paralytic ileus, or mild hepatitis can accompany the systemic vasculitis, occasionally leading to diagnostic confusion with surgical acute abdomen.
18. What specific central nervous system symptoms should be specifically inquired about during the history of an irritable infant with Kawasaki Disease?	1. Extreme, inconsolable irritability that is disproportionate to the degree of fever or pain. 2. Transient aseptic meningitis can occur, manifesting as neck stiffness, lethargy, or extreme fretfulness requiring careful clinical documentation.

Physical Examination & Bedside Signs

Question	Answer
1. What specific technique is used to inspect the bulbar conjunctiva in a suspected Kawasaki disease patient to identify the characteristic injection pattern?	Gently retract the lower eyelid while directing the child to look upward, ensuring visualization of the palpebral and bulbar conjunctiva while noting the absence of exudates and characteristic perilimbal sparing.
2. What exact physical sign is elicited when inspecting the oral mucosa of a child with Kawasaki disease, and which structure shows prominent hypertrophy?	Inspection reveals fiery red oral mucosa and dry, cracked lips, with hypertrophied fungiform lingual papillae protruding through a bright red coating, classic for a strawberry tongue.
3. How does the clinician palpate the hands and feet during the acute phase of Kawasaki Disease to assess extremity changes?	Palpation reveals tense, brawny, non-pitting induration across the palms and soles, accompanied by localized warmth and exquisite tenderness that elicits withdrawal or crying.
4. What functional bedside limitation is routinely observed in toddlers with acute phase Kawasaki disease due to extremity involvement?	Marked painful induration of the soles causes refusal or inability to bear weight, leading to a reluctant, stiff-legged toddler gait or refusal to walk altogether.
5. What specific bedside inspection finding appears in the perineal region during the acute phase of Kawasaki disease?	An accentuated, bright red, maculopapular exanthem over the perineum followed by early, characteristic sheet-like desquamation around the diaper area.
6. How must a clinical examiner properly palpate the cervical lymph nodes to document the defining criterion of Kawasaki-associated adenopathy?	Palpate the anterior cervical triangle using flat finger pads to identify a solitary, firm, non-suppurative lymph node measuring strictly ≥ 1.5 cm in its greatest dimension.
7. What specific dermatological sign should be purposefully sought on the upper arm during physical examination of an infant in India with prolonged fever?	Inspection of the prior left deltoid BCG vaccination site for localized erythema, induration, or central crusting, which indicates BCG scar reactivation.
8. What specific cardiovascular auscultatory finding may be detected during physical examination of a patient with giant coronary aneurysms or myocarditis?	A new gallop rhythm (S3 or S4) indicating myocardial dysfunction, or a systolic murmur at the apex secondary to mitral regurgitation from papillary muscle ischemia.
9. What abdominal palpation findings may be elicited in an infant with acute Kawasaki disease presenting with hydrops of the gallbladder?	A smooth, non-tender, palpable mass in the right upper quadrant representing a distended, non-inflamed gallbladder, often accompanied by right upper quadrant tenderness.
10. How does the exanthem of Kawasaki disease differ from viral exanthems upon close physical inspection?	Kawasaki rash is characteristically polymorphous—presenting as scarlatiniform, maculopapular, or erythema multiforme-like—and is notably devoid of vesicles, bullae, or pustules.
11. What specific ear, nose, and throat (ENT) physical finding helps differentiate Kawasaki pharyngitis from acute streptococcal pharyngitis?	Diffuse fiery redness of the pharyngeal mucosa is present, but unlike streptococcal pharyngitis, there is a complete absence of tonsillar exudates, petechiae, or a thick pseudomembrane.
12. VIVA TRAP: 15. VIVA TRAP: Can the presence of purulent conjunctival discharge and corneal ulceration be considered a variant of Kawasaki conjunctivitis?	NO. Kawasaki conjunctivitis is strictly non-exudative and spares the limbic margin; purulent discharge and corneal involvement point directly toward an infectious conjunctivitis or alternative diagnosis.
13. What skin sign can be elicited by applying firm digital pressure over the trunk in the subacute phase of Kawasaki disease?	Transitory blanching followed by accentuation of the polymorphous maculopapular rash, and in resolving phases, demonstration of transverse grooving of the nails known as Beau lines.
14. How should the clinician assess for peripheral edema during the physical examination of a child with suspected Kawasaki disease?	Firmly press the dorsum of the hands and feet for at least 5 seconds; Kawasaki edema is firm, brawny, and non-pitting, contrasting with soft pitting edema seen in nephrotic or cardiac failure.
15. What physical sign can be detected by gentle percussion and auscultation of the thorax in a patient with severe Kawasaki shock syndrome?	Dullness to percussion and diminished breath sounds at the lung bases due to reactive pleural effusions, alongside tachycardia disproportionate to fever and peripheral hypoperfusion.
16. VIVA TRAP: 3. VIVA TRAP: Can the absence of cervical lymphadenopathy entirely exclude the diagnosis of complete Kawasaki disease in a child with 5 days of persistent high-grade fever and the other 4 principal clinical criteria?	NO. The AHA diagnostic criteria require fever for at least 5 days plus the presence of at least 4 out of the 5 principal clinical criteria; therefore, cervical lymphadenopathy is not individually mandatory if all other 4 classical signs (conjunctivitis, oral changes, extremity changes, and rash) are fully present.

Diagnostic Criteria & Investigations

Question	Answer
1. What are the mandatory AHA 2017 diagnostic criteria required to establish a diagnosis of Complete (Classic) Kawasaki Disease?	1. Fever persisting for at least 5 days (can be diagnosed on day 4 if 4 principal signs are present). 2. Presence of at least 4 out of the 5 principal clinical criteria: bulbar conjunctival injection, oral mucosal changes, polymorphous exanthem, extremity changes, and cervical lymphadenopathy.
2. What exact laboratory parameter cutoffs define positive supplemental criteria when evaluating an incomplete Kawasaki Disease case?	1. CRP ≥ 3.0 mg/dL and/or ESR ≥ 40 mm/hr (mandatory gateway). 2. Positive supplemental criteria include albumin ≤ 3.0 g/dL, anemia for age, elevated ALT/AST, platelets > 450,000/uL after day 7, WBC ≥ 15,000/uL, and sterile pyuria (≥ 10 WBC/HPF).
3. What is the gold standard imaging modality for diagnosing and monitoring coronary artery abnormalities in Kawasaki disease?	Transthoracic echocardiography (TTE) is the gold standard, visualizing the left main coronary artery, left anterior descending artery, circumflex artery, and right coronary artery across multiple standard views.
4. How are coronary artery dimensions mathematically standardized and classified according to AHA echocardiographic guidelines?	Coronary dimensions are adjusted for body surface area into Z-scores: < 2.0 (normal), 2.0 to < 2.5 (dilation), 2.5 to < 5.0 (small aneurysm), 5.0 to < 10.0 (medium aneurysm), and ≥ 10.0 or absolute diameter ≥ 8 mm (giant aneurysm).
5. Which acute phase reactant serves as the primary gateway laboratory test to suspect incomplete Kawasaki disease in prolonged fever?	Serum C-Reactive Protein (CRP) ≥ 3.0 mg/dL (and/or ESR ≥ 40 mm/hr) serves as the obligatory inflammatory gateway test before evaluating the six supplemental laboratory criteria.
6. What specific liver function test abnormality is frequently observed as a supplemental laboratory criterion in acute Kawasaki Disease?	Mild to moderate transaminitis, specifically an elevation in serum alanine aminotransferase (ALT) and aspartate aminotransferase (AST), often accompanied by hyperbilirubinemia.
7. What cerebrospinal fluid (CSF) findings are characteristically found in Kawasaki patients who undergo lumbar puncture for aseptic meningitis?	Aseptic meningitis manifests as a lymphocytic pleocytosis in the CSF with normal glucose levels and normal to mildly elevated protein concentrations.
8. What radiological modality is indicated when coronary aneurysms are too large or complex to be adequately visualized by standard transthoracic echocardiography?	Coronary Computed Tomography Angiography (CCTA) or Cardiac Magnetic Resonance Imaging (CMRI) are utilized to delineate giant aneurysms, thrombosis, or distal lesions.
9. What electrocardiographic (ECG) abnormalities should the clinician anticipate during the acute phase of systemic inflammation?	ECG findings may demonstrate prolonged PR interval, ST-T wave abnormalities, low voltage, or arrhythmias indicative of acute myocarditis.
10. How does the differential diagnosis of Toxic Shock Syndrome (TSS) differentiate itself from Kawasaki Disease on laboratory evaluation?	TSS presents with profound multiorgan failure, early marked hypocalcemia, thrombocytopenia (unlike KD thrombocytosis), and positive cultures for toxin-producing Staph or Strep.
11. VIVA TRAP: 15. VIVA TRAP: Can a normal echocardiogram performed on the second day of persistent fever definitively rule out Kawasaki Disease?	NO. Coronary artery lesions rarely develop before Day 7 to 10 of illness; a normal echo early in the course does not exclude Kawasaki disease and must be repeated at Day 10-14 or if fever persists.
12. What specific urinary tract pathology can mimic sterile pyuria and must be excluded in infants suspected of having Kawasaki Disease?	A true urinary tract infection (UTI) with bacteriuria and positive urine cultures must be strictly ruled out, as Kawasaki pyuria is characteristically sterile due to sterile urethritis.
13. What diagnostic clues on complete blood count help differentiate systemic-onset Juvenile Idiopathic Arthritis (sJIA) from Kawasaki Disease?	sJIA typically presents with a much more striking leukocytosis (often > 20,000 to 30,000/uL with severe neutrophilia) and profound anemia out of proportion to fever duration, compared to KD.
14. What specific ultrasound finding in the right upper quadrant can support the diagnosis of acute Kawasaki Disease in a symptomatic toddler?	Hydrops of the gallbladder (gross distension of the gallbladder without gallstones or cystic duct obstruction) is a well-recognized sonographic finding in acute Kawasaki Disease.
15. What diagnostic biomarker cutoffs are utilized in predicting IVIG resistance (e.g., Kobayashi or Egami scoring systems) in Asian populations?	Scoring systems utilize parameters like serum sodium ≤ 133 mmol/L, AST > 100 IU/L, CRP > 10 mg/dL, platelets ≤ 300,000/uL, and age ≤ 12 months to predict non-response to primary IVIG therapy.
16. What specific immunological autoantibody panel is typically negative in Kawasaki Disease, helping differentiate it from connective tissue disorders?	Antinuclear antibodies (ANA), rheumatoid factor (RF), and anti-neutrophil cytoplasmic antibodies (ANCA) are characteristically negative in classical Kawasaki Disease.
17. According to the AHA 2017 criteria, what exact combination of fever duration, principal criteria, and supplemental laboratory findings defines Incomplete (Atypical) Kawasaki Disease in infants and children?	1. Persistent unexplained fever for ≥ 5 days accompanied by only 2 or 3 of the 5 principal clinical criteria. 2. Demonstration of systemic inflammation defined by an elevated CRP (≥ 3.0 mg/dL) and/or ESR (≥ 40 mm/hr). 3. Positivity for at least 3 of the 6 supplemental laboratory criteria (anemia for age, platelet count >450,000/µL after Day 7, serum albumin ≤ 3.0 g/dL, elevated ALT/AST, WBC ≥ 15,000/µL, or sterile pyuria ≥ 10 WBC/HPF), OR documentation of coronary artery abnormalities on echocardiography.
18. What precise echocardiographic Z-score threshold classifies a coronary artery lesion as a medium-sized aneurysm, and what is its absolute dimensional cutoff limit?	1. A medium-sized coronary artery aneurysm is defined by a BSA-adjusted Z-score ranging from 5.0 to < 10.0. 2. Additionally, the absolute internal lumen dimension must remain strictly less than 8 mm. 3. Any lesion meeting a Z-score ≥ 10.0 or an absolute lumen diameter ≥ 8 mm is reclassified as a giant aneurysm.

Evidence-Based Management & Pharmacotherapy

Question	Answer
1. At what point during treatment should high-dose aspirin be tapered to low-dose antiplatelet therapy?	High-dose aspirin is continued until the child has been afebrile for 48 to 72 hours, then reduced to a low antiplatelet dose.
2. What is the exact daily dose and duration for low-dose maintenance aspirin therapy following the acute phase?	Low-dose aspirin is given at 3 to 5 mg/kg/day once daily and maintained for 6 to 8 weeks in patients without coronary abnormalities.
3. Within what critical window from fever onset must initial IVIG therapy be administered to optimally prevent coronary artery aneurysms?	Initial IVIG must ideally be administered within the first 10 days of fever onset, and preferably within the first 7 days.
4. How is IVIG resistance defined in the clinical management of Kawasaki disease?	IVIG resistance is defined as the persistence or recrudescence of fever (at least 38.0 °C) 36 hours to 7 weeks after completing the initial IVIG infusion.
5. What constitutes the standard second-line rescue therapy for children who fail the first dose of IVIG?	A second dose of IVIG at 2.0 g/kg infused over 10 to 12 hours combined with systemic corticosteroids is the standard rescue protocol.
6. What is the preferred systemic corticosteroid regimen and dosing when treating IVIG-resistant Kawasaki disease?	Intravenous methylprednisolone pulse therapy at 30 mg/kg/day for 3 consecutive days is commonly utilized.
7. What alternative biological agent can be used as rescue therapy for refractory IVIG-resistant Kawasaki disease cases?	Infliximab, a chimeric monoclonal antibody against tumor necrosis factor-alpha, is administered as a single infusion of 5 mg/kg.
8. What specific live-attenuated vaccines must be temporarily deferred following high-dose IVIG therapy, and for how long?	Measles-mumps-rubella (MMR) and varicella vaccines must be deferred for 11 months following a high-dose IVIG infusion.
9. What mandatory infectious screening or prophylaxis must be considered before initiating anti-TNF therapy like infliximab in refractory cases?	Screening for latent tuberculosis infection using an IGRA or tuberculin skin test must be performed, along with ensuring up-to-date vaccinations.
10. What specific pharmacological modification is indicated in children who develop influenza or varicella while taking chronic low-dose aspirin?	Aspirin should be temporarily discontinued and replaced with alternative antiplatelet agents like clopidogrel to prevent Reye syndrome.
11. What therapeutic antithrombotic strategy is mandatory for patients who develop medium or giant coronary artery aneurysms?	Dual antiplatelet therapy (low-dose aspirin plus clopidogrel at 0.2 mg/kg/day) combined with therapeutic anticoagulation (low-molecular-weight heparin or warfarin) is indicated.
12. What primary mechanism explains the anti-inflammatory and immunomodulatory action of high-dose IVIG in Kawasaki vasculitis?	IVIG neutralizes circulating pathogenic autoantibodies, downregulates pro-inflammatory cytokines, inhibits complement activation, and induces Fc-gamma receptor blockade.
13. VIVA TRAP: 15. VIVA TRAP: Can routine administration of systemic corticosteroids be given as primary first-line monotherapy alongside aspirin instead of IVIG?	NEVER. Corticosteroid monotherapy as first-line treatment is not recommended as standard primary therapy, though recent Asian trials support adding steroids upfront to IVIG for high-risk patients.
14. What baseline laboratory monitoring is required prior to and during high-dose aspirin therapy in acute Kawasaki disease?	Serial monitoring of complete blood counts to check for hemoglobin levels, platelet counts, and baseline liver function tests for salicylate hepatotoxicity is required.
15. How does the American aspirin dosing regimen differ from Asian guidelines during the acute febrile phase?	The American Heart Association recommends a much higher anti-inflammatory dose of 80 to 100 mg/kg/day, whereas Asian protocols use 30 to 50 mg/kg/day to minimize bleeding and Reye risks.
16. What specific clinical signs of volume overload or adverse reactions must nurses monitor for during a high-dose IVIG infusion?	Nurses must watch for aseptic meningitis, transfusion-related acute lung injury (TRALI), acute kidney injury, severe headache, flushing, and signs of congestive heart failure.
17. What long-term cardiovascular surveillance and physical activity restrictions apply to a child who develops a giant coronary aneurysm?	Lifelong cardiology follow-up with serial imaging, strict avoidance of contact sports, and continuous dual antithrombotic therapy are mandatory.
18. What specific therapeutic intervention is indicated if an acute coronary thrombosis develops inside a giant Kawasaki aneurysm?	Emergency catheter-directed or systemic thrombolytic therapy using agents like tissue plasminogen activator (tPA) or mechanical thrombectomy is required.

High-Yield VIVA TRAPs & Examiner Pitfalls

Question	Answer
1. VIVA TRAP: Can a patient who presents on Day 12 of persistent fever be safely given IVIG and expect complete prevention of coronary artery aneurysms?	NEVER. IVIG should ideally be administered within the first 10 days of fever onset to prevent coronary aneurysms; however, treatment is still strongly recommended after Day 10 if there is ongoing systemic inflammation (elevated CRP/ESR) or new fever, or if coronary abnormalities are already present.
2. VIVA TRAP: Is routine administration of live-attenuated vaccines, such as MMR and Varicella, permitted immediately upon discharge after a child receives 2.0 g/kg of IVIG?	NO. High doses of exogenous immunoglobulins can suppress the immune response to live-attenuated vaccines, necessitating a mandatory deferral of MMR and Varicella vaccination for at least 11 months post-IVIG infusion.
3. VIVA TRAP: Should high-dose anti-inflammatory aspirin (30-50 mg/kg/day) be continued lifelong in a patient who has completely recovered without any coronary artery lesions?	NO. High-dose anti-inflammatory aspirin is discontinued once the child has been afebrile for 48 to 72 hours, transitioning to low-dose antiplatelet aspirin (3-5 mg/kg/day) only for 6 to 8 weeks if coronary arteries remain persistently normal (Z-score < 2.0).
4. VIVA TRAP: If a child with acute Kawasaki disease is allergic to aspirin, can ibuprofen or naproxen be safely substituted for antiplatelet and anti-inflammatory therapy?	NEVER. Non-steroidal anti-inflammatory drugs (NSAIDs) like ibuprofen competitively inhibit the acetylation site of platelets and can antagonize the irreversible antiplatelet effect of low-dose aspirin; clopidogrel is the preferred alternative antiplatelet agent in aspirin allergy.
5. VIVA TRAP: Can a second dose of IVIG (2.0 g/kg) be withheld in an IVIG-resistant child if their echocardiogram is entirely normal on Day 8 of illness?	NO. IVIG resistance is defined by persistent or recrudescent fever ≥ 36 hours after completing the first IVIG infusion, and immediate second-line therapy (second IVIG dose or pulsed methylprednisolone) is mandatory regardless of normal initial echocardiograms to halt ongoing vascular inflammation.
6. VIVA TRAP: Is therapeutic plasma exchange (TPE) indicated as a primary first-line intervention for uncomplicated Kawasaki disease presenting on Day 4 of fever?	NONE. Plasma exchange is entirely reserved for refractory, multi-line treatment-resistant Kawasaki disease cases associated with giant aneurysms or severe hemodynamic instability, never as first-line therapy.
7. VIVA TRAP: Should low-dose aspirin therapy be maintained indefinitely in a child who has documented regression and normalization of a previously medium-sized coronary aneurysm?	NO. Once coronary Z-scores normalize and remain < 2.0 on serial long-term echocardiographic surveillance, low-dose aspirin can typically be safely discontinued after cardiology consultation, whereas children with persistent aneurysms require lifelong dual or single antiplatelet therapy.
8. VIVA TRAP: Can an infant receiving chronic low-dose aspirin therapy continue taking it unchanged if they contract confirmed influenza or chickenpox?	NEVER. Children taking chronic aspirin who contract influenza or varicella are at severe risk of developing Reye syndrome; aspirin must be immediately stopped and substituted with an alternative antiplatelet agent like clopidogrel during viral illnesses.
9. VIVA TRAP: Is routine anticoagulant therapy with low-molecular-weight heparin or warfarin indicated for a patient who has normal coronary arteries and no signs of myocardial dysfunction?	NONE. Anticoagulation (heparin or oral anticoagulants) is strictly contraindicated in patients with normal coronary arteries or small dilations (Z-score 2.0 to < 2.5) due to bleeding risks; it is reserved exclusively for patients with medium, giant, or rapidly expanding aneurysms.
10. VIVA TRAP: Can a child with a giant coronary artery aneurysm (Z-score ≥ 10) be cleared for competitive contact sports and heavy weightlifting if they feel completely asymptomatic?	NEVER. Children with medium or giant coronary aneurysms must be strictly restricted from competitive, collision, and high-intensity contact sports due to the catastrophic risk of myocardial infarction, aneurysm rupture, or sudden cardiac death.
11. VIVA TRAP: Is it safe to dilute IVIG products in dextrose-containing intravenous fluids (e.g., 5% Dextrose) during administration to infants?	NO. IVIG preparations must be reconstituted and diluted strictly in normal saline (0.9% NaCl) or used undiluted according to manufacturer instructions; adding dextrose can cause precipitation or adverse physicochemical interactions.
12. VIVA TRAP: Can the diagnosis of IVIG resistance be established if a child has a brief, low-grade temperature spike (99.5°F) exactly 6 hours after completing the IVIG infusion?	NO. IVIG resistance requires persistent or recrudescent high-grade fever (≥ 38.0°C or 100.4°F) accompanied by ongoing clinical signs of inflammation occurring ≥ 36 hours and up to 7 days after the end of the initial IVIG infusion.
13. VIVA TRAP: Is infliximab administration safe without prior screening in a child slated to receive biologic rescue therapy for refractory Kawasaki disease?	NEVER. Prior to administering anti-TNF-alpha monoclonal antibodies like infliximab, mandatory screening for latent tuberculosis (Mantoux test or IGRA) and active infections must be performed to prevent dissemination of granulomatous disease.
14. VIVA TRAP: Should oral aspirin be continued at anti-inflammatory doses (50 mg/kg/day) throughout the entire 6-week convalescent phase of Kawasaki disease?	NO. High anti-inflammatory aspirin doses are maintained only during the acute febrile phase until the child is afebrile for 48–72 hours, after which it is abruptly stepped down to low-dose antiplatelet regimens (3-5 mg/kg/day) to avoid salicylate toxicity and Reye syndrome.
15. VIVA TRAP: Can prophylactic low-molecular-weight heparin be safely omitted in a child who has developed a giant coronary aneurysm if their coagulation profile is entirely normal?	NEVER. Giant coronary aneurysms (Z ≥ 10 or absolute lumen ≥ 8 mm) carry an extremely high, unacceptably severe risk of localized thrombus formation and myocardial infarction, mandating lifelong combined antiplatelet and therapeutic anticoagulation (warfarin or LMWH).
16. VIVA TRAP: Is routine administration of a second IVIG dose mandatory for all patients who show persistent fever after the first infusion, without considering corticosteroid rescue?	NO. While a second dose of IVIG is the traditional second-line choice, randomized trials and guidelines increasingly support pulsed intravenous methylprednisolone as an equally or more effective alternative rescue therapy for IVIG-resistant Kawasaki disease.
17. VIVA TRAP: Can the diagnostic criteria for complete Kawasaki disease be satisfied if the 5 principal clinical features appear transiently and resolve spontaneously before the 5th day of fever, without meeting the minimum fever duration?	NO. AHA 2017 guidelines strictly mandate that persistent fever of ≥ 5 days is an absolute baseline requirement for complete Kawasaki disease, regardless of whether all 5 classic mucocutaneous signs manifest earlier (though expert clinicians may initiate treatment on Day 4 if ≥ 4 criteria are present).
18. VIVA TRAP: Is it clinically acceptable to diagnose incomplete Kawasaki disease in an infant with unexplained fever for 3 days who exhibits prominent bilateral conjunctival injection and periungual desquamation?	NO. Desquamation is a late convalescent sign typically appearing only in the 2nd to 3rd week of illness, and an incomplete KD diagnosis requires a minimum of 5 days of fever along with elevated inflammatory markers and supplemental laboratory criteria.